Arcutis Biotherapeutics' (ARQT) Pipeline is Strong and Diversified, roflumilast cream Has High Approval Chance, Multiple Catalysts to Look Forward to - Mizuho
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear reiterated a Buy rating and $58.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
